Polyrizon Submits FDA Pre-Request for PL-16 Viral Blocker with Over 90% Efficacy Against Respiratory Viruses
核心洞察
Polyrizon Ltd. (搜索) has submitted a Pre-Request for Designation to the FDA for PL-16 Viral Blocker (搜索), a non-pharmacological intranasal spray designed to reduce exposure to influenza (搜索) and cold viruses through physical barrier formation.
In-vitro studies demonstrated that PL-16 preserved cell viability following exposure to influenza A (H1N1) (搜索) and human coronavirus 229E (搜索) by preventing viral access to cells with over 90% success rate.
The hydrogel-based product forms a muco-adhesive barrier on nasal mucosa (搜索) without systemic exposure or pharmacological activity, representing a novel approach to respiratory virus prevention.
Polyrizon Ltd. (搜索), a pre-clinical-stage biotechnology company, announced it has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration for its PL-16 Viral Blocker (搜索), marking a significant regulatory milestone for the novel intranasal protective technology. The non-pharmacological product demonstrated over 90% success in protecting cells against viruses in preclinical studies.
The Pre-RFD submission initiates formal regulatory dialogue with the FDA regarding the appropriate regulatory pathway for PL-16 Viral Blocker (搜索), based on its unique formulation and physical mode of action. This regulatory step comes during a challenging respiratory infection season, with CDC (搜索) preliminary estimates indicating the 2025-2026 flu season has already resulted in at least 2.9 million symptomatic illnesses, 1.4 million medical visits, 30,000 hospitalizations, and 1,200 deaths, including approximately 12 pediatric deaths.
Novel Barrier Technology Mechanism
PL-16 represents a departure from traditional pharmaceutical approaches to viral prevention. The metered-dose intranasal spray contains a hydrogel formulation composed of biodegradable polymers and standard excipients. Upon application, PL-16 forms a thin, muco-adhesive hydrogel layer that acts as a physical barrier, mechanically reducing contact between inhaled airborne particles and the nasal epithelium (搜索).
The product is designed for local, topical use only, with no systemic exposure and no intended pharmacological, immunological, or metabolic activity. This mechanism distinguishes it from conventional antiviral medications or vaccines, offering a purely mechanical approach to viral exposure reduction.
Comprehensive Preclinical Evidence Package
The Pre-RFD submission is supported by extensive in-vitro mechanistic studies demonstrating PL-16's physical blocking capabilities. Viral blocking efficacy studies showed that PL-16 preserved cell viability following exposure to influenza A (H1N1) (搜索) and human coronavirus 229E (搜索) by preventing viral access to cells.
Critical differentiation studies confirmed that viruses remain infective after being recovered from the PL-16 Viral Blocker (搜索) hydrogel, supporting a purely mechanical barrier mechanism rather than virucidal activity. Dynamic barrier validation through Transwell-based experiments demonstrated effective viral blocking over several hours under dynamic conditions, suggesting sustained protective capability.
Strategic Platform Development
The PL-16 Viral Blocker (搜索) program represents part of Polyrizon's broader strategy to develop non-medicated intranasal solutions designed to reduce exposure to airborne particles through physical barrier mechanisms. This approach builds on the company's existing Capture and Contain (C&C™) technology platform, which includes PL-14 Allergy Blocker (搜索) for reducing exposure to airborne allergens using similar non-pharmacological principles.
Polyrizon's proprietary C&C hydrogel technology comprises naturally occurring building blocks delivered as nasal sprays, potentially functioning as a "biological mask" with a thin shield containment barrier in the nasal cavity. The company is also developing Trap and Target™ (T&T) technology for intranasal delivery of active pharmaceutical ingredients, though this remains in earlier preclinical stages.
Market Context and Opportunity
According to Fortune Business Insights data cited by Polyrizon, the global nasal spray market was valued at USD 29.83 billion in 2024, with projections showing growth to USD 58.90 billion by 2032, representing a compound annual growth rate of 8.9% during the forecast period.
Seasonal respiratory infections (搜索) such as common cold (搜索) and influenza (搜索) represent a substantial global health and economic burden, with billions of episodes annually and significant costs from lost productivity and healthcare utilization. Despite this burden, most available preventive options are either pharmaceutical, symptom-focused, or vaccine-dependent, creating potential market opportunity for non-drug, locally acting solutions.
Regulatory Pathway Forward
Following receipt of Pre-RFD feedback from the FDA, Polyrizon will engage with the agency to align on next development steps for PL-16. The company continues advancing its intranasal platform toward additional indications focused on non-medicated, barrier-based respiratory protection.
The regulatory submission represents a critical step in translating Polyrizon's novel physical barrier approach from laboratory studies to potential clinical application, addressing the ongoing need for innovative preventive solutions against respiratory viral infections.